Anna M. Szota

9 Curie Skłodowskiej Street
Bydgoszcz, KP 85094, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Neurotrophins and Matrix Metalloproteinases in Treatment-Resistant Schizophrenia: Effects of Electroconvulsive Therapy on Serum Biomarkers and Clinical Outcomes: A Preliminary Study.

Neurotrophins and Matrix Metalloproteinases in Treatment-Resistant Schizophrenia: Effects of Electroconvulsive Therapy on Serum Biomarkers and Clinical Outcomes: A Preliminary Study.

Journal: Biomedicines

Published: May 17, 2026

Effect of Electroconvulsive Therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and Soluble IL-2 Receptor in Treatment-Resistant Schizophrenia (TRS) Patients-A Preliminary Study.

Effect of Electroconvulsive Therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and Soluble IL-2 Receptor in Treatment-Resistant Schizophrenia (TRS) Patients-A Preliminary Study.

Journal: Journal of clinical medicine

Published: March 17, 2025

Changes in IL-6, IL-12, IL-5, IL-10 and TGF-β1 Concentration in Patients with Treatment-Resistant Schizophrenia (TRS) Following Electroconvulsive Therapy (ECT)-A Pilot Study.

Changes in IL-6, IL-12, IL-5, IL-10 and TGF-β1 Concentration in Patients with Treatment-Resistant Schizophrenia (TRS) Following Electroconvulsive Therapy (ECT)-A Pilot Study.

Journal: Biomedicines

Published: October 22, 2024

The Influence of Electroconvulsive Therapy (ECT) on Brain-Derived Neurotrophic Factor (BDNF) Plasma Level in Patients with Schizophrenia-A Systematic Review and Meta-Analysis.

The Influence of Electroconvulsive Therapy (ECT) on Brain-Derived Neurotrophic Factor (BDNF) Plasma Level in Patients with Schizophrenia-A Systematic Review and Meta-Analysis.

Journal: Journal of clinical medicine

Published: July 27, 2023

Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review.

Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review.

Journal: Journal of clinical medicine

Published: April 14, 2023

Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges.

Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges.

Journal: Journal of psychoactive drugs

Published: August 03, 2021

The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: preclinical and clinical results.

The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: preclinical and clinical results.

Journal: Behavioural pharmacology

Published: May 28, 2020

Lamotrigine, quetiapine and aripiprazole-induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report.

Lamotrigine, quetiapine and aripiprazole-induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report.

Journal: BMC psychiatry

Published: October 22, 2019

The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.

The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.

Journal: International clinical psychopharmacology

Published: November 07, 2018

Sense of alexithymia in patients with anxiety disorders comorbid with recurrent urticaria.

Sense of alexithymia in patients with anxiety disorders comorbid with recurrent urticaria.

Journal: Neuropsychiatric disease and treatment

Published: May 05, 2016

A study of chemokines, chemokine receptors and interleukin-6 in patients with panic disorder, personality disorders and their co-morbidity.

A study of chemokines, chemokine receptors and interleukin-6 in patients with panic disorder, personality disorders and their co-morbidity.

Journal: Pharmacological reports : PR

Published: December 15, 2015

Serum concentrations of chemokines (CCL-5 and CXCL-12), chemokine receptors (CCR-5 and CXCR-4), and IL-6 in patients with posttraumatic stress disorder and avoidant personality disorder.

Serum concentrations of chemokines (CCL-5 and CXCL-12), chemokine receptors (CCR-5 and CXCR-4), and IL-6 in patients with posttraumatic stress disorder and avoidant personality disorder.

Journal: Pharmacological reports : PR

Published: October 14, 2014

Showing 1-12 of 20

Last Updated: 09/26/2026